Meniere Disease - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 43 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Meniere Disease - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Meniere Disease - Pipeline Review, H2 2014', provides an overview of the Meniere Disease's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Meniere Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Meniere Disease and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Meniere Disease
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Meniere Disease and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Meniere Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Meniere Disease pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Meniere Disease
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Meniere Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Meniere Disease Overview 6
Therapeutics Development 7
Pipeline Products for Meniere Disease - Overview 7
Pipeline Products for Meniere Disease - Comparative Analysis 8
Meniere Disease - Therapeutics under Development by Companies 9
Meniere Disease - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Meniere Disease - Products under Development by Companies 12
Meniere Disease - Companies Involved in Therapeutics Development 13
Orbis Biosciences, Inc. 13
Otonomy, Inc. 14
Quark Pharmaceuticals, Inc. 15
Synphora AB 16
Xigen SA 17
Meniere Disease - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
betamethasone valerate - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
dexamethasone acetate SR - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
latanoprost - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
siRNA for CNS Disorders - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
XG-102 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Meniere Disease - Recent Pipeline Updates 34
Meniere Disease - Product Development Milestones 37
Featured News & Press Releases 37
Dec 01, 2014: Otonomy Achieves Patient Enrollment Target in Phase 2b Clinical Trial of OTO-104 in Meniere's Disease 37
Oct 09, 2014: Otonomy Enrolls First Meniere's Disease Patients in OTO-104 Multiple-Dose Safety Study 37
Dec 11, 2013: Otonomy Enrolls First Patient in Pivotal Phase 2b Study of OTO-104 in Meniere's Disease 38
Sep 29, 2011: Otonomy Presents Positive New Findings From Phase Ib Study Of OTO-104 In Meniere's Disease At International Conference 39
Apr 28, 2011: Otonomy Announces Positive Results From Phase Ib Study Of OTO-104 In M�ni�re's Disease 40
Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 43
Disclaimer 43

List of Tables
Number of Products under Development for Meniere Disease, H2 2014 7
Number of Products under Development for Meniere Disease - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Clinical Stage Development, H2 2014 10
Comparative Analysis by Early Stage Development, H2 2014 11
Products under Development by Companies, H2 2014 12
Meniere Disease - Pipeline by Orbis Biosciences, Inc., H2 2014 13
Meniere Disease - Pipeline by Otonomy, Inc., H2 2014 14
Meniere Disease - Pipeline by Quark Pharmaceuticals, Inc., H2 2014 15
Meniere Disease - Pipeline by Synphora AB, H2 2014 16
Meniere Disease - Pipeline by Xigen SA, H2 2014 17
Assessment by Monotherapy Products, H2 2014 18
Number of Products by Stage and Target, H2 2014 20
Number of Products by Stage and Mechanism of Action, H2 2014 22
Number of Products by Stage and Route of Administration, H2 2014 24
Number of Products by Stage and Molecule Type, H2 2014 26
Meniere Disease Therapeutics - Recent Pipeline Updates, H2 2014 34